Karyopharm Therapeutics (KPTI) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to -$63.7 million.
- Karyopharm Therapeutics' Enterprise Value rose 5589.69% to -$63.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$63.7 million, marking a year-over-year increase of 5589.69%. This contributed to the annual value of -$63.7 million for FY2025, which is 5589.69% up from last year.
- As of Q4 2025, Karyopharm Therapeutics' Enterprise Value stood at -$63.7 million, which was up 5589.69% from -$45.9 million recorded in Q3 2025.
- Over the past 5 years, Karyopharm Therapeutics' Enterprise Value peaked at -$45.9 million during Q3 2025, and registered a low of -$278.0 million during Q4 2022.
- In the last 5 years, Karyopharm Therapeutics' Enterprise Value had a median value of -$181.1 million in 2022 and averaged -$170.9 million.
- Its Enterprise Value has fluctuated over the past 5 years, first plummeted by 4039.2% in 2023, then soared by 6601.65% in 2025.
- Quarter analysis of 5 years shows Karyopharm Therapeutics' Enterprise Value stood at -$228.6 million in 2021, then fell by 21.59% to -$278.0 million in 2022, then surged by 31.13% to -$191.4 million in 2023, then increased by 24.5% to -$144.5 million in 2024, then skyrocketed by 55.9% to -$63.7 million in 2025.
- Its Enterprise Value stands at -$63.7 million for Q4 2025, versus -$45.9 million for Q3 2025 and -$51.7 million for Q2 2025.